Presentation on theme: "2013 PR & Communications Plan 20 September 2012 Ilaris (ACZ885, canakinumab) This document represents proposals for discussion by Management. Strategies."— Presentation transcript:
2013 PR & Communications Plan 20 September 2012 Ilaris (ACZ885, canakinumab) This document represents proposals for discussion by Management. Strategies / Concepts / Projects described herein may need significant modifications before implementation, and no project should be considered final until it has been fully approved by the appropriate Novartis review process. Novartis will only implement programs that are fully consistent with all applicable laws and regulations as well as Novartis companies’ policies. The sales estimates described in this document are based on the impact of Marketing Activities.
2 Who is with you here today Rote Frazao Marques Global Head, Franchise Communications IHC Helene Ellison Senior strategist Global Chair, B-M (NY) Deborah Burrage Day-to-day client lead Manager, B-M (London) Sarah Cornhill Account strategic lead Director, B-M (NY) | 2013 PR & Communications Plan
3 Today’s agenda 2013 PR strategy built on five Ilaris PR strategic imperatives Our strategic and creative vision to drive the Ilaris value story Our vision for the future Critical steps to take in 2013 Ilaris programming Orchestration for success | 2013 PR & Communications Plan
4 Ilaris to 2014 and beyond: ensuring success through multiple launches QUESTIONSADDRESSED (SJIA+GA) ENSURE SUCCESSFUL LAUNCHES & UPTAKE; (AI) UNDERSTAND MARKET 2014 (SJIA+GA) ENSURE CONTINUED GROWTH; (AI) ENSURE SUCCESSFUL LAUNCHES & UPTAKE | 2013 PR & Communications Plan
5 Our charge… Highlight Ilaris value proposition, emphasizing unmet need and establishing Novartis leadership in drug discovery for an innovative, targeted approach to treating inflammatory conditions | 2013 PR & Communications Plan
6 SI1 Your strategic imperatives adapted for PR Emphasize unmet needs of target patient populations to reconfirm Ilaris unique value proposition Ensure understanding of IL-1B as key driver of inflammatory conditions, linked to Novartis laser- focus on science Expand scientific and community understanding of Ilaris efficacy and safety Continue to identify, up-skill and harness Ilaris product and disease champions (internal and external) Ensure market preparedness for upcoming launches | 2013 PR & Communications Plan SI1SI2SI3SI4SI5